Long-term Safety and Efficacy of Difelikefalin in Subjects With Chronic Kidney Disease–Associated Pruritus: Analysis From KALM-1 and KALM-2

Main Article Content

Steve Fishbane
Warren Wen
Catherine Munera
Frédérique Menzaghi
Kieran McCafferty


safety, efficacy, difelikefalin, CKD, pruritis




1. Albert-Vartanian A, et al. J Clin Pharm Ther. 2013;9:e23-e31.

2. Aldrich JV, et al. Drug Discov Today Technol. 2016;41:371-382.

3. Spencer RH, et al. J Am Soc Nephrol. 2016;27:338A.

4. Fishbane S, et al. N Engl J Med. 2020;382:222-232.

5. Wooldridge TD, et al. J Am Soc Nephrol. 2020;31(suppl):22-23.

6. Korsuva [package insert]. Stamford, CT: Cara Therapeutics, Inc.; August 2021.

7. Elman S, et al. Br J Dermatol. 2010;162:587-593.

8. United States Renal Data System. 2020 USRDS Annual
Data Report: Epidemiology of kidney disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2020.

Most read articles by the same author(s)